5-[(benzyloxy)methyl]-7-bromo-4-chloro-5H-pyrrolo[3,2-d]pyrimidine | 1010701-76-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯并嘧啶类
• 英文名称: 5-[(benzyloxy)methyl]-7-bromo-4-chloro-5H-pyrrolo[3,2-d]pyrimidine
• 英文别名: 7-bromo-5-(benzyloxymethyl)-4-chloro-5H-pyrrolo[3,2-d]pyrimidine；7-Bromo-5-(benzyloxymethyl)-4-chloro-5h-pyrrolo[3,2-d]pyrimidine；7-bromo-4-chloro-5-(phenylmethoxymethyl)pyrrolo[3,2-d]pyrimidine
• CAS: 1010701-76-4
• 化学式: C₁₄H₁₁BrClN₃O
• 分子量: 352.618
• InChiKey: UTZREODFYDFNIQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  20
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  39.9
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  5-[(benzyloxy)methyl]-7-bromo-4-chloro-5H-pyrrolo[3,2-d]pyrimidine 在 正丁基锂 、 2-甲基吡啶-N-甲硼烷 、 氨 、 一水合肼 、 钯 、 三乙胺 作用下， 以 甲醇 、 乙醚 、 正己烷 为溶剂， 反应 46.5h， 生成 (2S)-2-[({4-amino-5H-pyrrolo[3,2-d]pyrimidin-7-yl}methyl)amino]-3-(methylsulfanyl)propan-1-ol
  参考文献：
  名称：

  Transition state analogue inhibitors of human methylthioadenosine phosphorylase and bacterial methylthioadenosine/S-adenosylhomocysteine nucleosidase incorporating acyclic ribooxacarbenium ion mimics

  摘要：

  Several acyclic hydroxy-methylthio-amines with 3-5 carbon atoms were prepared and coupled via a methylene link to 9-deazaadenine. The products were tested for inhibition against human MTAP and Escherichia coli and Neisseria meningitidis MTANs and gave K-i values as low as 0.23 nM. These results were compared to those obtained with 1st and 2nd generation inhibitors (1S)-1-(9-deazaadenin-9-yl)-1,4-dideoxy-1,4-imino-5-methylthio-D-ribitol (MT-Immucillin-A, 3) and (3R,4S)-1-[9-deazaadenin-9-yl)methyl]3-hydroxy-4-methylthiomethylpyrrolidine (MT-DADMe-Immucillin-A, 4). The best inhibitors were found to exhibit binding affinities of approximately 2- to 4-fold those of 3 but were significantly weaker than 4. Cleavage of the 2,3 carbon-carbon bond in MT-Immucillin-A (3) gave an acyclic product (79) with a 21,500 fold loss of activity against E. coli MTAN. In another case, N-methylation of a side chain secondary amine resulted in a 250-fold loss of activity against the same enzyme [(+/-)-65 vs (+/-)-68]. The inhibition results were also contrasted with those acyclic derivatives previously prepared as inhibitors for a related enzyme, purine nucleoside phosphorylase (PNP), where some inhibitors in the latter case were found to be more potent than their cyclic counterparts. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2012.07.006
• 作为产物：
  描述：

  苄基氯甲基醚 在 sodium hydride 、 N-溴代丁二酰亚胺(NBS) 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 反应 3.83h， 以56.9%的产率得到5-[(benzyloxy)methyl]-7-bromo-4-chloro-5H-pyrrolo[3,2-d]pyrimidine
  参考文献：
  名称：

  WO2008/30119

  摘要：

  公开号：

文献信息

• Acyclic amine inhibitors of nucleoside phosphorylases and hydrolases
  申请人：Clinch Keith

  公开号：US20110130412A1

  公开（公告）日：2011-06-02

  The invention relates to compounds of the general formula (I) which are inhibitors of purine nucleoside phosphorylases (PNPs) and/or nucleoside hydrolases (NHs). The invention also relates to the use of these compounds in the treatment of diseases and infections including cancer, bacterial infections, protozoal infections, and T-cell mediated disease and to pharmaceutical compositions containing the compounds.

  本发明涉及一般式(I)的化合物，其为嘌呤核苷酸磷酸酯酶（PNP）和/或核苷酸水解酶（NH）的抑制剂。本发明还涉及这些化合物在治疗疾病和感染，包括癌症，细菌感染，原虫感染和T细胞介导的疾病中的使用，以及含有这些化合物的制药组合物。
• ACYCLIC AMINE INHIBITORS OF NUCLEOSIDE PHOSPHORYLASES AND HYDROLASES
  申请人：INDUSTRIAL RESEARCH LIMITED

  公开号：EP2057165A1

  公开（公告）日：2009-05-13
• US8853224B2
  申请人：——

  公开号：US8853224B2

  公开（公告）日：2014-10-07
• [EN] ACYCLIC AMINE INHIBITORS OF NUCLEOSIDE PHOSPHORYLASES AND HYDROLASES<br/>[FR] AMINES ACYCLIQUES INHIBITEURS DES PHOSPHORYLASES ET HYDROLASES DE NUCLÉOSIDES
  申请人：IND RES LTD

  公开号：WO2008030119A1

  公开（公告）日：2008-03-13

  [EN] The invention relates to compounds of the general formula (I) which are inhibitors of purine nucleoside phosphorylases (PNPs) and/or nucleoside hydrolases (NHs). The invention also relates to the use of these compounds in the treatment of diseases and infections including cancer, bacterial infections, protozoal infections, and T-cell mediated disease and to pharmaceutical compositions containing the compounds.
  [FR] La présente invention concerne des composes représentés par la formule générale (I), et des compositions pharmaceutiques contenant ces composés, lesquels composés sont des inhibiteurs des phosphorylases de nucléosides de purine (PNP) et/ou d'hydrolases de nucléosides (NH). L'invention concerne également l'utilisation de ces composés pour le traitement de maladies et d'infections dont le cancer, les infections bactériennes, les infections par protozoaires, et les maladies médiées par les lymphocytes T.
• Transition state analogue inhibitors of human methylthioadenosine phosphorylase and bacterial methylthioadenosine/S-adenosylhomocysteine nucleosidase incorporating acyclic ribooxacarbenium ion mimics
  作者：Keith Clinch、Gary B. Evans、Richard F.G. Fröhlich、Shivali A. Gulab、Jemy A. Gutierrez、Jennifer M. Mason、Vern L. Schramm、Peter C. Tyler、Anthony D. Woolhouse

  DOI：10.1016/j.bmc.2012.07.006

  日期：2012.9

  Several acyclic hydroxy-methylthio-amines with 3-5 carbon atoms were prepared and coupled via a methylene link to 9-deazaadenine. The products were tested for inhibition against human MTAP and Escherichia coli and Neisseria meningitidis MTANs and gave K-i values as low as 0.23 nM. These results were compared to those obtained with 1st and 2nd generation inhibitors (1S)-1-(9-deazaadenin-9-yl)-1,4-dideoxy-1,4-imino-5-methylthio-D-ribitol (MT-Immucillin-A, 3) and (3R,4S)-1-[9-deazaadenin-9-yl)methyl]3-hydroxy-4-methylthiomethylpyrrolidine (MT-DADMe-Immucillin-A, 4). The best inhibitors were found to exhibit binding affinities of approximately 2- to 4-fold those of 3 but were significantly weaker than 4. Cleavage of the 2,3 carbon-carbon bond in MT-Immucillin-A (3) gave an acyclic product (79) with a 21,500 fold loss of activity against E. coli MTAN. In another case, N-methylation of a side chain secondary amine resulted in a 250-fold loss of activity against the same enzyme [(+/-)-65 vs (+/-)-68]. The inhibition results were also contrasted with those acyclic derivatives previously prepared as inhibitors for a related enzyme, purine nucleoside phosphorylase (PNP), where some inhibitors in the latter case were found to be more potent than their cyclic counterparts. (C) 2012 Elsevier Ltd. All rights reserved.